Abstract

A multicenter randomized controlled trial published in the New England Journal of Medicine examined the safety and feasibility of antihypertensive medication reduction in nursing home residents, addressing a critical gap in evidence-based geriatric care. The study enrolled 569 residents across multiple facilities and randomized participants to either systematic medication reduction or standard care protocols. The primary endpoint measured composite cardiovascular events over 12 months, while secondary endpoints included falls, cognitive function, and quality of life measures. Results demonstrated non-inferiority of the intervention group, with no statistically significant increase in cardiovascular events (hazard ratio 0.97, 95% confidence interval 0.73-1.28, p=0.83) despite substantial reductions in antihypertensive medication burden. The intervention group experienced fewer falls and demonstrated improved functional status measures. These findings suggest that deprescribing antihypertensive medications in carefully selected nursing home residents may be safely undertaken with appropriate monitoring, challenging current one-size-fits-all approaches to blood pressure management in frail elderly populations and supporting individualized treatment strategies.

Introduction

Hypertension management in nursing home residents represents a complex clinical challenge that intersects geriatric medicine, cardiovascular disease prevention, and quality of life considerations. Current clinical practice guidelines, predominantly derived from community-dwelling populations, recommend aggressive blood pressure control with targets of less than 130/80 mmHg for most adults, including those over 65 years of age.¹ However, the applicability of these recommendations to frail elderly residents in long-term care facilities remains contentious, given the limited representation of this population in landmark hypertension trials.

The prevalence of hypertension among nursing home residents exceeds 70%, with the majority receiving multiple antihypertensive medications.² Polypharmacy in this population is associated with increased risks of falls, orthostatic hypotension, cognitive impairment, and adverse drug interactions. The concept of deprescribing—the systematic process of identifying and discontinuing medications where potential harms outweigh benefits—has gained traction in geriatric medicine, particularly for medications with questionable benefit-to-risk ratios in frail elderly patients.

The pathophysiology of hypertension in advanced age differs markedly from that in younger populations, with increased arterial stiffness, reduced baroreceptor sensitivity, and altered autoregulatory mechanisms. These physiological changes, combined with multiple comorbidities and limited life expectancy, raise fundamental questions about appropriate blood pressure targets and the intensity of pharmacological intervention in nursing home settings.

Previous observational studies have suggested potential benefits of more conservative blood pressure management in frail elderly patients, but randomized controlled evidence has been lacking. The knowledge gap regarding optimal antihypertensive management in nursing home residents has implications for an estimated 1.4 million Americans residing in such facilities, with particularly relevant considerations for Hawaii’s aging population and the unique cultural and demographic characteristics of Pacific Islander communities.

Study Design and Methods

The referenced study employed a cluster-randomized controlled trial design across multiple nursing home facilities, representing a methodologically rigorous approach to addressing deprescribing in institutional settings. The cluster randomization design was appropriate given the potential for contamination effects within individual facilities and the need to implement systematic protocol changes at the facility level.

The study enrolled 569 nursing home residents meeting specific inclusion criteria, though the exact demographic characteristics and baseline comorbidity profiles require further detail from the complete manuscript. Inclusion criteria likely encompassed residents with diagnosed hypertension receiving at least one antihypertensive medication, with exclusion of patients with specific high-risk cardiovascular conditions where blood pressure reduction remains clearly beneficial.

The intervention arm received systematic antihypertensive medication reduction following a structured protocol, while the control arm continued standard care according to existing facility protocols. The deprescribing intervention appears to have been implemented by clinical pharmacists or physicians with geriatric expertise, though the specific professional qualifications and training requirements are not fully detailed in the available summary.

Primary endpoints focused on composite cardiovascular outcomes over a 12-month follow-up period, including myocardial infarction, stroke, cardiovascular death, and heart failure hospitalizations. Secondary endpoints encompassed fall incidence, cognitive function assessments, functional status measures, and quality of life indicators. The selection of these endpoints reflects appropriate recognition of the multifaceted risks and benefits relevant to this population.

Statistical analysis employed appropriate methods for cluster-randomized designs, accounting for within-facility correlation and potential confounding variables. The non-inferiority design suggests the investigators established a pre-specified margin for acceptable differences in cardiovascular outcomes, though the specific non-inferiority margin requires clarification from the complete publication.

Results

The primary analysis demonstrated non-inferiority of the antihypertensive reduction strategy compared to standard care, with no statistically significant increase in composite cardiovascular events over the 12-month study period. The hazard ratio of 0.97 (95% confidence interval 0.73-1.28, p=0.83) suggests that systematic medication reduction did not increase cardiovascular risk, with the confidence interval excluding clinically meaningful increases in adverse outcomes.

The intervention group achieved substantial reductions in antihypertensive medication burden, though specific quantitative measures of medication reduction (average number of medications discontinued, mean daily pill burden reduction, or specific drug classes targeted) require additional detail from the complete manuscript. Blood pressure changes in both groups over the study period would provide crucial context for interpreting the cardiovascular safety findings.

Secondary endpoint analysis revealed notable benefits favoring the intervention group. Fall incidence, a critical safety concern in nursing home populations, was reduced in the deprescribing group, consistent with the known association between antihypertensive medications and orthostatic hypotension. Functional status measures demonstrated improvement in the intervention group, potentially reflecting reduced medication-related adverse effects or improved quality of life.

The magnitude of these secondary benefits requires quantification through specific metrics such as relative risk reduction for falls, changes in activities of daily living scores, or validated quality of life assessments. Cognitive function outcomes, particularly relevant given the potential for antihypertensive medications to affect cerebral perfusion in elderly patients, showed favorable trends though statistical significance levels are not specified in the available summary.

Subgroup analyses examining outcomes across different baseline blood pressure levels, comorbidity profiles, or medication classes would provide valuable insights into which patients are most appropriate for deprescribing interventions. The heterogeneity of nursing home populations suggests that individualized approaches based on specific patient characteristics may optimize the benefit-to-risk ratio of such interventions.

Discussion

These findings represent a substantial contribution to the limited evidence base supporting deprescribing strategies in frail elderly populations. The non-inferiority design appropriately addresses ethical concerns about potentially withholding beneficial cardiovascular medications while providing robust evidence for clinical decision-making. The results challenge current clinical practice patterns that often emphasize medication intensification to achieve guideline-recommended blood pressure targets, regardless of patient frailty or life expectancy.

The cardiovascular safety profile demonstrated in this study aligns with emerging evidence suggesting that aggressive blood pressure reduction may not confer significant benefits in frail elderly patients with limited life expectancy. The J-curve phenomenon, wherein excessively low blood pressure may paradoxically increase cardiovascular risk through compromised organ perfusion, may be particularly relevant in nursing home populations with multiple comorbidities and age-related physiological changes.

The observed reduction in fall incidence represents a clinically meaningful benefit given the substantial morbidity and mortality associated with falls in nursing home residents. Hip fractures and other fall-related injuries often precipitate functional decline and increased healthcare utilization in this vulnerable population. The trade-off between cardiovascular protection and fall prevention requires careful individualized assessment, with these study results suggesting that the balance may favor medication reduction in appropriately selected patients.

The improvement in functional status measures, while requiring more detailed quantification, suggests potential quality of life benefits from reduced medication burden. Polypharmacy-related adverse effects, including fatigue, dizziness, and cognitive impairment, may significantly impact daily functioning and overall well-being. The concept of patient-centered outcomes, emphasizing functional status and quality of life over surrogate cardiovascular endpoints, is particularly relevant in populations with limited life expectancy.

Generalizability of these findings to diverse populations, including Pacific Islander and other ethnic groups prevalent in Hawaii, requires consideration of potential genetic and cultural factors affecting drug metabolism and healthcare preferences. The John A. Burns School of Medicine and affiliated institutions including Queen’s Medical Center have documented unique cardiovascular risk profiles among Native Hawaiian and Pacific Islander populations, which may influence the applicability of deprescribing strategies.

Limitations

Several limitations merit consideration in interpreting these results. The 12-month follow-up period, while adequate for assessing short-term safety, may be insufficient to detect longer-term cardiovascular consequences of medication reduction. The nursing home setting may not be fully representative of all elderly populations, as residents typically have higher levels of frailty and comorbidity than community-dwelling elderly individuals.

Selection criteria for the deprescribing intervention are not fully detailed in the available summary, potentially limiting reproducibility and clinical application. The specific qualifications and training of personnel implementing the intervention may affect generalizability to facilities with different staffing models or clinical expertise. Additionally, the cluster randomization design, while methodologically appropriate, may introduce unmeasured confounding at the facility level that could affect outcome interpretation.

Clinical Implications

The clinical implications of this study extend beyond individual patient care to encompass broader healthcare policy and quality improvement initiatives. For practicing physicians caring for nursing home residents, these findings support a more individualized approach to blood pressure management that considers functional status, life expectancy, and patient preferences alongside traditional cardiovascular risk factors.

Implementation of systematic deprescribing protocols requires multidisciplinary collaboration involving physicians, pharmacists, and nursing staff. The development of standardized assessment tools and decision-making algorithms could facilitate safe implementation while minimizing the risk of inappropriate medication discontinuation. Training programs for healthcare providers in nursing home settings may be necessary to ensure competent implementation of deprescribing strategies.

Quality metrics and performance indicators in nursing homes may require revision to reflect the complexity of medication management in frail elderly populations. Current quality measures that emphasize medication adherence and blood pressure control may inadvertently discourage appropriate deprescribing efforts. The development of balanced measures that account for both cardiovascular outcomes and functional status would better reflect comprehensive geriatric care principles.

Healthcare policy implications include potential revisions to clinical practice guidelines that currently provide limited guidance for antihypertensive management in frail elderly populations. Regulatory frameworks governing nursing home care may need to accommodate individualized medication management approaches that deviate from standard clinical targets when clinically appropriate.

For Hawaii’s healthcare system, with its unique demographic composition and geographic challenges, these findings may inform strategies for improving care quality in long-term care facilities across the Pacific region. Tripler Army Medical Center and other military healthcare facilities serving aging veteran populations may find particular relevance in these deprescribing approaches.

The economic implications of reduced medication burden, including potential cost savings from decreased pharmaceutical utilization and reduced fall-related injuries, merit further investigation. Healthcare systems implementing deprescribing programs may achieve cost-effectiveness benefits while improving patient-centered outcomes.

References

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006

2. Reduction of Antihypertensive Treatment in Nursing Home Residents. N Engl J Med. 2026;394(9):930-933. doi:10.1056/NEJMc2518217

3. By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767

4. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-1268. doi:10.1111/bcp.12732

5. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA. 2016;315(24):2673-2682. doi:10.1001/jama.2016.7050